Cynata Therapeutics Ltd (ASX:CYP) has seen its share price rise more than 10% on the release of a study indicating the potential for Cymerus – its ‘off the shelf’ therapeutic stem cell platform technology – to reverse pulmonary fibrosis and lung stiffness. The study – which was conducted by Professor Chrishan Samuel, Head of the Fibrosis Laboratory at Monash University’s Department of Pharmacology – aimed to examine the efficacy of Cymerus in the treatment of idiopathic pulmonary fibrosis (IPF) – an often-fatal chronic lung disease in humans. However, the study subjects in this case were mice …